Abetimus

DB06662InvestigationalNucleic Acid Based Therapies

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Primary indication: Investigated for use/treatment in kidney disease and systemic lupus erythematosus.Curator reviewed

Resolves to

Compound

UNIIP3UVQ22SHKCAS167362-48-3

Clinical / RWD

RxNorm1311600ATCL04AA22

What you can answer from here — as of July 17, 2026

363Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 7 drug categories

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Abetimus, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account